Antonio Giordano, Clinical Director at Dana-Farber Cancer Institute, shared on X:
”21.5% of all metastatic cancers have a tissue agnostic indication, including 5.4% that lack a cancer-specific indication.
Dr. Mahadevan reviewing clinical advances in Antibody Drug Conjugates development and novel payloads. Really enjoyed this quick escape to NYC for the STOPcancer2026 drug development and precision medicine in cancer.”
Other articles about STOPcancer2026 OncoDaily.
